文献速递临床试验与 GCP基础与转化研究

BIONYX试验:Resolute Onyx与Orsiro药物洗脱支架在冠脉疾病全 comers中的非劣效性比较

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
PubMed 文献 · Lancet · 2018-09-22

BIONYX是一项国际、单盲、随机非劣效性试验,纳入2516例接受PCI的全 comers患者,比较Resolute Onyx与Orsiro支架。

要点

  • Resolute Onyx支架1年靶血管失败率非劣效于Orsiro支架。
  • Resolute Onyx组支架血栓发生率显著低于Orsiro组。
  • 两组事件率均低,提示两种支架安全性良好。

核心结论

  • 在全 comers人群中,Resolute Onyx支架1年复合安全性和有效性终点非劣效于Orsiro支架。
  • Resolute Onyx组支架血栓发生率很低,值得进一步临床研究。

研究设计与样本

  • 研究者发起的、评估者盲和患者盲、随机非劣效性试验,在比利时、以色列和荷兰的7个独立监测中心进行。
  • 纳入2516例年龄≥18岁、需要药物洗脱支架行PCI的患者,按1:1随机分配至Resolute Onyx或Orsiro支架,随机化按性别和糖尿病状态分层。

临床怎么用

  • 对于接受PCI的冠脉疾病全 comers患者,Resolute Onyx支架可作为Orsiro支架的替代选择,1年靶血管失败风险非劣效。
  • Resolute Onyx支架可能降低支架血栓风险,但需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During the past decade, many patients had zotarolimus-eluting stents implanted, which had circular shape cobalt-chromium struts with limited radiographic visibility. The Resolute Onyx stent was developed to improve visibility while reducing strut thickness, which was achieved by using a novel composite wire with a dense platinum-iridium core and an outer cobalt-chromium layer. We did the first randomised clinical trial to assess the safety and efficacy of this often-used stent compared with the Orsiro stent, which consists of ultrathin cobalt-chromium struts. METHODS: We did an investigator-initiated, assessor-blinded and patient-blinded, randomised non-inferiority trial in an allcomers population at seven independently monitored centres in Belgium, Israel, and the Netherlands. Eligible participants were aged 18 years or older and required percutaneous coronary intervention with drug-eluting stents. After guide wire passage with or without predilation, members of the catheterisation laboratory team used web-based computer-generated allocation sequences to randomly assign patients (1:1) to either the Resolute Onyx or the Orsiro stent. Randomisation was stratified by sex and diabetes status. Patients and assessors were masked to allocated stents, but treating clinicians were not. The primary endpoint was target vessel failure at 1 year, a composite of cardiac death, target-vessel-related myocardial infarction, and target vessel revascularisation, and was assessed by intention to treat (non-inferiority margin 2·5%) on the basis of outcomes adjudicated by an independent event committee. This trial is registered with ClinicalTrials.gov, number NCT02508714. FINDINGS: Between Oct 7, 2015, and Dec 23, 2016, 2516 patients were enrolled, 2488 of whom were included in the intention-to-treat analysis (28 withdrawals or screening failures). 1243 participants were assigned to the Resolute Onyx group, and 1245 to the Orsiro group. Overall, 1765 (70·9%) participants presented with acute coronary syndromes and 1275 (51·2%) had myocardial infarctions. 1-year follow-up was available for 2478 (99·6%) patients. The primary endpoint was met by 55 (4·5%) patients in the Resolute Onyx group and 58 (4·7%) in the Orsiro group. Non-inferiority of Resolute Onyx to Orsiro was thus established (absolute risk difference -0·2% [95% CI -1·9 to 1·4]; upper limit of the one-sided 95% CI 1·1%; pnon-inferiority=0·0005). Definite or probable stent thrombosis occurred in one (0·1%) participant in the Resolute Onyx group and nine (0·7%) in the Orsiro group (hazard ratio 0·11 [95% CI 0·01-0·87]; p=0·0112). INTERPRETATION: The Resolute Onyx stent was non-inferior to Orsiro for a combined safety and efficacy endpoint at 1-year follow-up in allcomers. The low event rate in both groups suggests that both stents are safe, and the very low rate of stent thrombosis in the Resolute Onyx group warrants further clinical investigation. FUNDING: Biotronik and Medtronic.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet. 2018. PMID: 30253879. doi:10.1016/S0140-6736(18)32001-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。